Disitamab Vedotin: Promising HER2-Targeted Therapy for Urothelial Cancer - Matthew Galsky
Preliminary results from the RC48G001 Study Cohort C show a 75% response rate with disitamab vedotin plus pembrolizumab in HER2-expressing metastatic urothelial cancer, with activity in both HER2-positive and HER2-low tumors. The safety profile differs from enfortumab vedotin plus pembrolizumab, potentially distinguishing it. Dr. Galsky emphasizes the importance of HER2 and FGFR3 biomarker testing in all metastatic urothelial cancer patients, noting 60-80% of tumors express HER2, and highlights the ongoing phase III study comparing this combination to platinum-based chemotherapy.
Reference News
Preliminary results from the RC48G001 Study Cohort C show a 75% response rate with disitamab vedotin plus pembrolizumab in HER2-expressing metastatic urothelial cancer, with activity in both HER2-positive and HER2-low tumors. The safety profile differs from enfortumab vedotin plus pembrolizumab, potentially distinguishing it. Dr. Galsky emphasizes the importance of HER2 and FGFR3 biomarker testing in all metastatic urothelial cancer patients, noting 60-80% of tumors express HER2, and highlights the ongoing phase III study comparing this combination to platinum-based chemotherapy.